Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study
유재민, 백현준, 박성민, Yi Ha-Woo, 남석진, 김석원, 이세경, 유종한, 배수연, 이정언,
소속 상세정보
유재민 ( Ryu Jai-Min )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
백현준 ( Paik Hyun-June )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
박성민 ( Park Sung-Min )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
( Yi Ha-Woo )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
남석진 ( Nam Seok-Jin )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
김석원 ( Kim Seok-Won )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
이세경 ( Lee Se-Kyung )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
유종한 ( Yu Jong-Han )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
배수연 ( Bae Soo-Youn )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
이정언 ( Lee Jeong-Eon )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Surgery
KMID : 1134120170200010074
Abstract
Purpose: The use of immediate breast reconstruction (IBR) following total mastectomy (TM) has increased markedly in patients with breast cancer. As the indications for IBR have been broadened and more breast-conserving surgery-eligible patients are undergoing IBR, comparing the oncologic safety between TM only and IBR following TM becomes more difficult. This study aimed to analyze the oncologic outcomes between TM only and IBR following TM via a matched case-control methodology.
Methods: A retrospective review was conducted to identify all patients who underwent TM between 2008 and 2014. We excluded patients who underwent neoadjuvant chemotherapy, including palliative chemotherapy, and had a follow-up duration <12 months, inflammatory breast cancer, or incomplete data. We divided the remaining patients into two groups: those who underwent TM only (control group) and those who underwent IBR following TM (study group). The groups were propensity score-matched. Matched variables included age, pathologic stage, estrogen or progesterone receptor status, human epidermal growth factor receptor 2 status, and year of operation.
Results: After matching, 878 patients were enrolled in the control group and 580 patients in the study group. The median follow-up duration was 43.4 months (range, 11?100 months) for the control group and 41.3 months (range, 12?100 months) for the study group (p=1.000). The mean age was 47.3±8.46 years for the control group and 43.9±7.14 years for the study group (p>0.050). Matching was considered successful for the matching variables and other factors, such as family history, histology, multiplicity, and lymphovascular invasion. There were no significant differences in overall survival (log-rank p=0.454), disease-free survival (log-rank p=0.186), local recurrence-free survival (log-rank p=0.114), or distant metastasis-free survival rates (logrank p=0.537) between the two groups.
Conclusion: Our results suggest that IBR following TM is a feasible treatment option for patients with breast cancer.
키워드
Breast neoplasms; Mammaplasty; Treatment outcome
원문 및 링크아웃 정보
등재저널 정보